Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Agree Realty Corp (ADC) Ajinomoto Co Inc (AJINY) Amerisafe Inc (AMSF) Bayer AG (BAYRY) Blackboard Inc (BBBB) Carriage Services Inc (CSV) Celera Corp (CRA) China Information Security Tech Inc (CPBY) DeVry Inc (DV) Dynamics Research Corp (DRCO) EF Johnson Technologies Inc (EFJI) Elbit Systems Ltd (ESLT) FiberTower Corp (FTWR) First California Financial Group Inc (FCAL) Flanders Corp (FLDR) Gmarket Inc (GMKT) Greatbatch Inc (GB) Kaman Corp (KAMN) LaCrosse Footwear Inc (BOOT) LJ International Inc (JADE) Magnetek Inc (MAG) Metabasis Therapeutics Inc (MBRX) Moog Inc (MOG.A) NCI Inc (NCIT) Novartis AG (NVS) Osteologix Inc (OLGX) Pegasystems Inc (PEGA) Power Medical Interventions Inc (PMII) Pressure BioSciences Inc (PBIO) ...

Investors turn to the large drug company stocks for several reasons. They are considered recession proof, they are a play on the ageing of the baby boomers, and they are often considered safer and less volatile than most other stocks. Since dividends are so vital to many investors they days, the high yielding big pharmas are of interest. All of the following have yields over 2.5%, PE's below 20, and PEGs below 3.Pfizer Inc. (PFE) Its drugs include Lipitor, Norvasc Caduet, Chantix/Champix, Lyrica, Geodon/Zeldox, Aricept, Zoloft, Celebrex, Vfend, Zyvox, Viagra, Detrol, and Zyrtec, and for animals; Clavamox/Synulox, RespiSureOne/StellamuneOne, Bovi-Shield Gold, Dectomax, and Draxxin. The stock yields 7.5% It has a PE of 12.7 and a PEG of 2.12 .Bristol Myers Squibb Co. (BMY) Its drugs include PLAVIX, AVAPRO/AVALIDE, PRAVACHOL, COUMADIN, REYATAZ, SUSTIVA, BARACLUDE, ERBITUX, TAXOL, SPRYCEL, IXEMPRA, ABILIFY, ORENCIA, and EFFERALGAN. The ...

Brains, Benchmarks, and Best SectorsStockerblog.com had the pleasure of recently interviewing Ken Fisher, head of the $30 billion Fisher Asset Management, a very long time Forbes columnist, and author of the books Super Stocks, The Wall Street Waltz, 100 Minds That Made the Market, and The Only Three Questions That Count: Investing by Knowing What Others Don't. He is also coming out with a new book in the Fall, The Ten Roads to Riches: The Way the Wealthy Got There (And How You Can Too!), published by Wiley.If you missed any of the earlier segments of the interview, you can check them out: Part 1, ...

The Price Sales RatioStockerblog.com had the pleasure of recently interviewing Ken Fisher, head of the $30 billion Fisher Asset Management, a very long time Forbes columnist, and author of the books Super Stocks, The Wall Street Waltz, 100 Minds That Made the Market, and The Only Three Questions That Count: Investing by Knowing What Others Don't. He is also coming out with a new book in the Fall, The Ten Roads to Riches: The Way the Wealthy Got There (And How You Can Too!), published by Wiley.Stockerblog.com: Talking a little about the Price to Sales Ratio, which you discussed extensively in your Super Stocks...